If you have been reading about CJC-1295 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-05-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (with DAC) | ~3647 Da | Calculated from the full amino acid sequence |
| Molecular weight (without DAC) | ~3368 Da | Mod GRF(1-29) variant |
| Appearance | White lyophilized powder | Typical form supplied for research |
| Solubility | Soluble in water | Dissolves in aqueous buffers |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
=== Archaea === Archaea have a single type of RNAP, responsible for the synthesis of all RNA. Archaeal RNAP is structurally and mechanistically similar to bacterial RNAP and eukaryotic nuclear RNAP I-V, and is especially closely structurally and mechanistically related to eukaryotic nuclear RNAP II. The history of the discovery of the archaeal RNA polymerase is quite recent. The first analysis of the RNAP of an archaeon was performed in 1971, when the RNAP from the extreme halophile Halobacterium cutirubrum was isolated and purified. Crystal structures of RNAPs from Sulfolobus solfataricus and Sulfolobus shibatae set the total number of identified archaeal subunits at thirteen. Archaea has the subunit corresponding to Eukaryotic Rpb1 split into two. There is no homolog to eukaryotic Rpb9 (POLR2I) in the S. shibatae complex, although TFS (TFIIS homolog) has been proposed as one based on similarity. There is an additional subunit dubbed Rpo13; together with Rpo5 it occupies a space filled by an insertion found in bacterial β′ subunits (1,377–1,420 in Taq). An earlier, lower-resolution study on S. solfataricus structure did not find Rpo13 and only assigned the space to Rpo5/Rpb5. Rpo3 is notable in that it's an iron–sulfur protein. RNAP I/III subunit AC40 found in some eukaryotes share similar sequences, but does not bind iron. This domain, in either case, serves a structural function. Archaeal RNAP subunit previously used an "RpoX" nomenclature where each subunit is assigned a letter in a way unrelated to any other systems.
=== Oxidative metabolism === Evidence suggests that mitochondrial dysfunction is present in people with bipolar disorder. Oxidative stress and reduced levels of anti-oxidants (such as glutathione) lead to cell death. Lithium may protect against oxidative stress by up-regulating complexes I and II of the mitochondrial electron transport chain.
They were characterized by producing flowers in spring on the previous year's wood, and often again in summer or early autumn on the current year's growth. The former Fortunei Group (also known as Florida Group, although it had nothing to do with C. florida) comprised cultivars with double or semi-double flowers that were produced on the previous year's growth in spring. Hybridization has made it impossible to keep the original Groups separate: there are a number of cultivars that produce both single and double flowers, or that only produce semi-double or double flowers under certain conditions. Late Large-flowered Group: Comprises the former Lanuginosa Group and Jackmanii Group. Cultivars of the Lanuginosa Group were derived mainly from C. lanuginosa, either directly or indirectly. The Jackmanii Group covered cultivars produced from a cross between C. viticella (or a derivative therefrom) and a member of the Patens Group. Both Groups produce their flowers on the current year's growth in summer and autumn. It is often impossible to say whether a cultivar belongs to the Lanuginosa Group or to the Jackmanii Group, due to hybridization and/or lack of information on the parentage, so it is not possible to maintain these Groups.
== Institutional responses to criticism of the impact factor == Given the growing criticism and its widespread usage as a means of research assessment, organisations and institutions have begun to take steps to move away from the journal impact factor. In November 2007 the European Association of Science Editors (EASE) issued an official statement recommending "that journal impact factors are used only—and cautiously—for measuring and comparing the influence of entire journals, but not for the assessment of single papers, and certainly not for the assessment of researchers or research programmes". In July 2008, the International Council for Science Committee on Freedom and Responsibility in the Conduct of Science issued a "statement on publication practices and indices and the role of peer review in research assessment", suggesting many possible solutions—e.g., considering a limit number of publications per year to be taken into consideration for each scientist, or even penalising scientists for an excessive number of publications per year—e.g., more than 20.
=== Septic arthritis === PCT at a cutoff value of .5 ng/mL was effective at ruling in septic arthritis in an analysis of over 8000 patients across 10 prospective studies. PCT had a sensitivity of 54% and specificity of 95%. The study also concluded that PCT outperforms C-reactive protein in differentiating septic arthritis from non-septic arthritis.
Sources: en.wikipedia.org
The recall had been ordered after several ships in TF 58 picked up radar contacts 150 miles (240 km) to the west around 10:00. This was the first of the raids from the Japanese carrier forces, with 68 aircraft. TF 58 started launching every fighter it could; by the time they were in the air the Japanese had closed to 70 miles (110 km). However, the Japanese began circling to regroup their formations for the attack. This 10-minute delay proved critical, and the first group of Hellcats met the raid, still at 70 miles (110 km), at 10:36. They were quickly joined by additional groups. Within minutes, 25 Japanese aircraft had been shot down, against the loss of only one U.S. aircraft. The Japanese aircraft that survived were met by other fighters, and 16 more were shot down. Of the 27 aircraft which remained, some made attacks on the picket destroyers USS Yarnall and Stockham but caused no damage. Between three and six bombers broke through to Lee's battleship group and attacked; one bomb hit the main deck of USS South Dakota, killing or injuring over 50 men but failing to disable her. South Dakota was the only American ship damaged in this attack. No aircraft of Ozawa's first wave got through to the American carriers.
=== Vitamin A supplementation === Vitamin A deficiency is a major factor in causing blindness worldwide, particularly among children. Global vitamin A supplementation efforts have targeted 103 priority countries. Flour fortification has become an increasingly common method by which vitamin A can be added to diets thus reducing deficiencies.
Napoleon's Wars: An International History, 1803–1815. Penguin Books. ISBN 978-0-14-311628-8. Ferguson, Niall (2008). The Ascent of Money: A Financial History of the World: 10th Anniversary Edition. Penguin. ISBN 978-1-4406-5402-2. Fremont-Barnes, Gregory (2014). The Napoleonic Wars (3): The Peninsular War 1807–1814. Bloomsbury Publishing. ISBN 978-1-4728-0975-9. Gates, David (1986). The Spanish Ulcer: A History of the Peninsular War. Allen & Unwin. ISBN 978-0-04-940079-5. Glover, Michael (1963). Wellington's Peninsular Victories: Busaco, Salamanca, Vitoria, Nivelle. Macmillan. Götz, Norbert (6 June 2014). "The Good Plumpuddings' Belief: British Voluntary Aid to Sweden During the Napoleonic Wars". The International History Review. 37 (3): 519–539. doi:10.1080/07075332.2014.918559. ISSN 0707-5332. Grab, Alexander (2003). Napoleon and the Transformation of Europe. Macmillan International Higher Education. ISBN 978-1-4039-3757-5. Grainger, John D. (2004). The Amiens Truce: Britain and Bonaparte, 1801–1803. Boydell Press. ISBN 978-1-84383-041-2. Gray, Colin S. (2007). War, Peace and International Relations: An Introduction to Strategic History. Routledge. ISBN 978-1-134-16951-1. Halévy, Elie (1924). A History of the English People ...: England in 1815. Harcourt, Brace. Haythornthwaite, Philip; et al. (Illustrations and graphics by Peter Dennis) (20 September 2012). Cowper, Marcus (ed.). Borodino 1812: Napoleon's great gamble. Campaign. Vol. 246. London, England, United Kingdom of Great Britain: Bloomsbury Publishing. ISBN 9781849086974.
== Neuromodulator == GSSG, along with glutathione and S-nitrosoglutathione (GSNO), have been found to bind to the glutamate recognition site of the NMDA and AMPA receptors (via their γ-glutamyl moieties), and may be endogenous neuromodulators. At millimolar concentrations, they may also modulate the redox state of the NMDA receptor complex.
==== MeSH E05.181.724 – ultracentrifugation ==== MeSH E05.181.724.336 – centrifugation, density gradient MeSH E05.181.724.336.253 – centrifugation, isopycnic MeSH E05.181.724.336.336 – centrifugation, zonal
Sources: en.wikipedia.org
The physics of FTICR is similar to that of a cyclotron at least in the first approximation. In the simplest idealized form, the relationship between the cyclotron frequency and the mass-to-charge ratio is given by
== Pharmaceuticals == The vaccine vial monitors are a family of TTIs used by the World Health Organization to track the degradation of vaccines. This is important as many places in the world do not have a reliable cold chain and vaccines tend to spend some time not refrigerated. Based on data on how long a vaccine stays useful at different temperatures, a VVM that matches the vaccine's degradation behavior is chosen. The VVM takes into account all heat exposures except for small peaks. TTIs are also used to protect other heat-sensitive drugs, many of which are complex biologics. Vaccines are a kind of biologics.
Appointed by the president, the prime minister is supported by the party or political alliance with a majority of seats in the lower house of parliament. The executive of the Indian government consists of the president, the vice-president, and the Union Council of Ministers—with the cabinet being its executive committee—headed by the prime minister. Any minister holding a portfolio must be a member of one of the houses of parliament. In the Indian parliamentary system, the executive is subordinate to the legislature; the prime minister and their council are directly responsible to the lower house of the parliament. Civil servants act as permanent executives, and all decisions of the executive are implemented by them. India has a three-tier unitary independent judiciary comprising the supreme court, headed by the Chief Justice of India, 25 high courts, and a large number of trial courts. The supreme court has original jurisdiction over cases involving fundamental rights and over disputes between states and the centre and has appellate jurisdiction over the high courts. It has the power to both strike down Union or State laws which contravene the Constitution and invalidate any government action it deems unconstitutional. In recent years, India has experienced democratic erosion, in which a combination of institutional passivity, negligence, and political meddling have crippled the ability of the Supreme Court, the Election Commission of India, and other federal agencies to restrain an executive branch and ruling party partial to majoritarian Hindu nationalism.
== Taxonomy and phylogeny == Pholcus phalangioides was first described in 1775 by the Swiss entomologist Johann Kaspar Füssli. A member of the genus Pholcus in the family Pholcidae, P. phalangioides shares ancestry with roughly 1,340 similar cellar-spiders. All of these spiders are known for their characteristic long legs, which can range from 5 to 6 times the size of their bodies. This is not to be confused with organisms with similar physical appearances, such as the crane fly – an insect – and harvestmen of the arachnid order Opiliones.
Since the 1990s, large cities across China have moved traditional outdoor markets to modern indoor facilities. As of 2018, fresh food markets remained the most prevalent food outlet in urban regions of China despite the rise of supermarket chains since the 1990s. During the 2010s, "smart markets" equipped with e-payment terminals emerged as traditional markets faced increasing competition from discount stores. Such markets also began facing competition from online grocery stores, such as Alibaba's Hema stores. The trade of wildlife is not common in China, particularly in large cities, and most food markets in China do not contain live or wild animals besides fish held in tanks. In the early 1980s, small-scale wildlife farming began under the reform and opening up. It began to expand nationwide with government support in the 1990s, but was largely concentrated in the southeastern provinces. In 2003, markets across China were banned from holding wildlife after the 2002–2004 SARS outbreak, which was directly tied to such practices. Some poorly regulated Chinese markets provided outlets for the wildlife trade industry after the ban, although the illegal wildlife trade in China was predominantly in fur rather than in food or medicine. The Huanan Seafood Wholesale Market in Wuhan was linked to the origin of COVID-19 due to its early cluster of cases, leading to further restrictions and enforcement in 2020. In April 2020, the Chinese government unveiled plans to further tighten restrictions on wildlife trade.
Sources: en.wikipedia.org
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.
The maleimide group forms a covalent link with albumin, an abundant blood protein. This attachment slows clearance, so a single administration persists much longer than the unmodified peptide. The feature is the main reason the two variants are handled differently in study design.
It is not an approved therapeutic product in major regulatory jurisdictions. It appears in research chemical catalogs and scientific literature rather than pharmacy shelves. Clinical development was limited and did not reach approval.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.